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Summary. Objective. The aim of this study was to investigate the effects of bupropion sustained 
release (SR) on cognitive function, evaluated by event-related potentials (ERPs), in heavy tobacco 
smokers. 
Material and Methods. A total of 10 healthy volunteers (6 men and 4 women) were enrolled into 
the study. P3a and P3b components were evaluated by the novelty P3 paradigm. The ERP record-
ings were taken after the overnight abstaining and the first dose on the 1st day, on the 7th day, and 
45th day of the therapy. 
Results. The analysis of electrophysiological data in response to the standard stimuli in the 
parietal area after 7-day bupropion SR treatment revealed a significant increase in the P2 laten-
cy (P<0.05). With respect to the drug use × topography effect, an increasing trend of borderline 
signi fi cance in the P3b and P2 amplitudes against target events in the parietal area was observed 
(P=0.08 for both). A significant increase in the P3a amplitude in the parietocentral area was also 
observed on the seventh day of treatment (P<0.05).
Conclusions. The reduction of P3a in the frontal area may be due to the decreased distractibility 
of task-irrelevant novel events, which may mean an augmentation of focused attention to task-rele-
vant target events. The increases in the P3b and P2 amplitudes for target events in the parietal area 
are very suggestive of this hypothesis, since these components reflect the response to task-relevant 
target events. Meanwhile, the increased P2 latency for standard events may reflect reduced atten-
tion resources for the processing of standard events due to increased attention resources allocated 
for task-relevant target events. Decreased distractibility and increased attention are believed to be 
caused by bupropion.
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bul Faculty of Medicine, Istanbul University, 34093 Capa, Is-
tanbul, Turkey. E-mail: atillauslu_itf@hotmail.com
Introduction
Tobacco use continues to be the leading global 
cause of preventable death. According to the World 
Health Organization (WHO) report on the global 
tobacco epidemic 2011, it kills nearly 6 million peo-
ple. If current trends continue, it is estimated that 
tobacco will kill more than 8 million people world-
wide each year by 2030 (1, 2). Turkey is facing a 
serious tobacco epidemic as well. Nearly 17.6 mil-
lion of the nation’s adults are smokers (3), and more 
than 100 000 people die each year due to smoking, 
a number estimated to increase to 240 000 deaths 
by 2030 (4).
Bupropion HCl, a new-generation nontricyclic 
antidepressant, has been used for smoking cessation 
therapies worldwide since it took an FDA’s new in-
dication approval in 1997. It is known to be the first 
licensed nonnicotine-based pharmacological thera-
py for smoking cessation (5–8). Although its exact 
mechanism of action is unknown, it is assumed that it 
exerts its action via dopamine and/or noradrenaline 
re-uptake inhibition. Additionally, its mild activat-
ing effects of the central nervous system are linked 
to dopaminergic mechanisms, and its antidepressant 
activity is essentially associated with long-term no-
radrenergic mechanisms (9–11). Recent research has 
also demonstrated that bupropion sustained release 
(SR) acts as a nicotine antagonist (12).
The studies investigating bupropion effects on a 
reward pathway showed that it induced increased ex-
tracellular dopamine in the nucleus accumbens (9, 
13–15), and bupropion SR self-administration up-
regulated dopamine transporters in a dose-depend-
ent manner in the caudate putamen and the nucleus 
accumbens (16). Furthermore, bupropion SR has 
been found to increase dose-dependent [3H] spiper-
one binding in the striatum (17), and bupropion SR 
infusion into the neostriatum increased extracellular 
dopamine in a dose-dependent manner (18).
Since the mesolimbic dopamine system is re-
garded as the last common pathway of dependence 
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and the neuroanatomical basis of the reinforcing ef-
fects, it is assumed that dopaminergic mechanisms 
play the main role in smoking cessation to decrease 
nicotine craving and dysphoria due to abstinence. 
On the other hand, it has been suggested that bu-
propion SR is a functional inhibitor of nicotinic ace-
tylcholine receptors (nAChRs) in both the muscle 
and the ganglia (19), and it blocks α3β2, α4β2, and 
a7 neuronal nAChRs with some degree of selectiv-
ity (20). On the contrary, Young and Glennon (21) 
have shown that bupropion SR displayed a nicotine-
like stimulation effect in a two-lever drug discrimi-
nation task, but did not act like an antagonist as 
mecamylamine did. 
For a better understanding of the action mech-
anisms of a psychopharmacological agent, the 
evaluation of its effects on patients by using the 
well-established neuropsychological tests and neu-
rophysiological measurements is important. Event-
related potentials (ERPs) as noninvasive electro-
physiological measures of perceptual and cognitive 
processes are well-suited for such an evaluation. 
They consist of a series of peaks and troughs, which 
appear in the ongoing electroencephalogram (EEG) 
in response to occurrence of discrete events, such as 
presentation of a stimulus (22, 23).
One of the most extensively studied endogenous 
ERP components is the P3 wave. It occurs in re-
sponse to rare and task-relevant stimuli (target stim-
uli) among a series of frequent (standard) stimuli. 
It is a positive wave with a maximum amplitude in 
the parietal scalp area and has a typical peak latency 
of 300–600 ms that reflects the speeds of stimu-
lus identification and categorization. On the other 
hand, the amplitude of P3 is inversely proportional 
to the rarity of presentation, i.e., probability. Thus, 
it is believed that P3 indicates on-line updating of 
working memory (24–27). It reflects a process of 
memory updating by which the current model of 
environment is modified as a function of incoming 
information. However, it can also be used as an in-
dex of attention function as it is modulated by at-
tention. 
If the third “novel” event is added to the classical 
“oddball paradigm,” a positive component differ-
ent from P3 is observed. Having an earlier latency 
than the target P3 (P3b) and a distribution more 
frontally, it is called P3a. It is thought to reflect the 
distractibility to novel events, such as a dog bark 
or a door creak, among standard and target tones. 
The P3a component reflects initial processing when 
a novel or distracting stimulus is detected, where-
as P3b reflects the subsequent attention resources 
when a target stimulus engages memory operations 
during task performance (28–30).
Neuropsychological tests also serve as useful 
tools to measure the cognitive effects from a behav-
ioral perspective. A Continuous Performance Test 
(CPT), which can measure processing speed in ad-
dition to focused and sustained attention, might be 
useful in evaluating the effects of bupropion SR on 
the attention system. Furthermore, a wide variety 
of presentation methods (auditory, visual, or verbal) 
and performance measures, such as hit rate, com-
mission (impulsivity), and omission (inattention), 
can be used in this test (31). Other test, the Digit-
Symbol Substitution Test (DSST), a derivative of 
the Wechsler Adult Intelligence Scale-Digit Symbol 
Test, can be used as a measure of psychomotor per-
formance, motor persistence, sustained attention, 
response speed, visuomotor coordination, and per-
ceptual organization (32).
This study evaluated the ERP and behavioral 
data from heavy tobacco smokers being treated at 
the Smoking Cessation Outpatient Clinic (Depart-
ment of Chest Diseases, Istanbul Faculty of Med-
icine, Istanbul University). The aim of this study 
was to investigate the effects of bupropion SR on 
cognitive functions as measured by ERPs in heavy 
tobacco smokers by evaluating the electrophysi-
ological and behavioral evidences. We aimed to as-
sess whether bupropion SR acted as a nicotine-like 
stimulant or not, and whether these effects served 
as a possible substitute for smoking during absti-
nence. For such an evaluation, P3a measures could 
enable us to evaluate the distractibility of the patient 
during abstinence, and by P3b, it would be possible 
to discuss if focused attention was impaired. Two 
arousal states can be mentioned according to the 
complementary roles for dopamine and noradrena-
line in the mediation of arousal states (33, 34): upper 
and lower arousal mechanisms. The “upper” arousal 
mechanism (mediated by noradrenaline) modu-
lates the activity of the “lower” arousal mechanism 
(mediated by dopamine). Therefore, dopamine or 
noradrenaline-based bupropion effects can be inves-
tigated using the cognitive evidence from P3a and 
P3b. 
 
Material and Methods
This study was conducted in accordance with the 
Declaration of Helsinki. Participants were informed 
about the test paradigm and ERP recording proce-
dures; all subjects gave written informed consent.
Participants. Ten healthy volunteers (6 men and 
4 women) participated in the study. The demo-
graphic characteristics and smoking history (mean 
age, years smoked, and cigarettes per day) of the 
participants are presented in Table 1. All partici-
pants underwent physical examination, had good 
physical, pulmonary, and mental health, did not use 
any medications known to affect the central nervous 
system, and were free of neurological or psychiatric 
disorders. The participants with a history of hepatic 
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and renal failure were excluded from study as bu-
propion is known to be extensively metabolized in 
the liver to active metabolites and excreted by the 
kidneys. The Fagerström Test for Nicotine Depend-
ence (FTND) was used for assessing nicotine de-
pendence (32). This test is a 6-item measure that is 
scored between 0 and 10, with higher scores reflect-
ing greater nicotine dependence (35). 
The patients were given the standard bupropion 
SR tablet (Zyban®, GlaxoSmithKline, Research 
Triangle Park, NC) therapy at a dosage of 150 mg/
day for the first 3 days and then 150 mg twice daily 
thereafter for a study period of 7 weeks. The tar-
get day for quitting smoking was 1 week after the 
beginning of the therapy. Although the major side 
effects of bupropion are nausea or vomiting, in-
somnia, dizziness and headaches, these side effects 
were not observed in the subjects of our study. The 
patients were invited for the first recording in the 
morning after overnight abstinence. The second re-
cording was taken on the same day after the first 
dose of bupropion SR (150 mg) with an adequate 
time interval for the peak plasma concentration dur-
ing recording (36, 37).
By the first and second recordings, it was ex-
pected to see the acute effects of the drug during 
abstinence. Considering that the drug reached a 
steady state concentration on the seventh day of the 
treatment, the third recording was taken while the 
patient was still smoking. The fourth recording was 
taken on the 45th day, which was within the last 
week of the therapy. The first three recordings were 
taken from all of the patients, whereas the last week 
participation was low due to failure to quit smok-
ing. Additionally, the CPT and the DSST were car-
ried out before the recordings for a general neu-
ropsychological evaluation. It took approximately 
10 minutes to complete these tests, including the 
warm-up period.
ERP Recording Conditions. EEGs were recorded 
in the Electroneurophysiology Laboratory, Depart-
ment of Physiology. The participants were comfort-
ably seated in an armchair in a dimly illuminated, 
sound-attenuated, and electrically shielded room. 
Electrical activity of the brain was recorded using 
Ag/AgCl EEG ring electrodes at F3, Fz, F4, C3, 
Cz, C4, T3, T4, P3, Pz, P4, O1, Oz, O2 electrode 
locations according to the extended international 
10/20 placement system with a forehead ground. 
To observe the eye movement artifacts, electro-ocu-
logram (EOG) activity was recorded bipolarly from 
two-cup electrodes located at the outer canthus of 
the right eye and the nasion. Electromyography 
(EMG) electrodes were located in the metaphalan-
geal area to track the extension of the index finger. 
Electrode impedance was kept below 20 kΩ. EEG 
and EOG were amplified by a La Mont®, 32-chan-
nel EEG type 2 amplifier (Wisconsin 53719, USA) 
with a band pass filter of 0.1–70 Hz and digitized 
with a sampling rate of 256 Hz and stored on the 
hard disk of a PC for off-line analysis.
Stimuli and Procedure. Stimulus presentation was 
carried out by a MATLAB® program. ERPs were 
recorded while the subjects performed auditory and 
visual tasks. 
Auditory Novelty Oddball Task. For a cognitive 
evaluation, the novelty P3 experiment with stand-
ard, target, and novel auditory stimuli was applied. 
The stimuli were 1000-Hz (standard), 2000-Hz (tar-
get) tones of 50-ms duration, and novel stimuli, 
such as a dog bark or door creak, which were pre-
sented at 80 dB with an interstimulus interval (ISI) 
of 2000 ms. The two different tones and the novel 
stimuli were presented in a random order, such that 
the probabilities of the standard, target, and novel 
stimuli were 60%, 20% and 20% of the 300 total 
trials, respectively. The patient was instructed to re-
spond to target tones by the extension of the index 
finger of the right hand, which was measured using 
two EMG electrodes located on the metaphalangeal 
area.  
Visual Continuous Performance Test. The patients 
were given a visual CPT, in which a series of let-
ters were presented on a computer screen as visual 
stimuli. A total of 400 letters were presented in each 
trial, each letter appearing 160 ms with an ISI of 800 
ms. The patient was seated comfortably in front of 
the computer and instructed to respond to the “A”s, 
which appeared after the “Z”s, but not the other 
“A”s. The response to each stimulus and the reac-
tion time was saved on the computer for analysis. 
To measure the performance, reaction time (for the 
hits) and hit rate, omission, and commission scores 
were evaluated.
Neuropsychological Assessment. The DSST was 
administrated to 10 heavy tobacco smokers being 
treated at the Smoking Cessation Outpatient Clinic. 
The DSST used was a classical paper and pencil test, 
in which the patient was asked to match the digits 
(1–9) with a specific symbol. There were 2 tables in 
the test. The upper table contained 10 symbols, each 
Variable Value
Male-to-female ratio
Age, years 
Education, years
Smoking history, years 
No. of cigarettes per day 
FTND, score*
6:4
42.0 (11.8) [23–62]
13.1 (2.6) [8–15]
20.6 (9.3) [5–30]
32.0 (9.2) [20–40]
7.6 (2.2) [6–12]
Values are mean (standard deviation) [range] unless otherwise 
indicated.
FTND, Fagerström Test for Nicotine Dependence. 
*A score of 6 and more indicates nicotine dependence.
Table 1. Demographic Characteristics and Smoking History 
of Patients (n=10)
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of which was paired with a digit between 1 and 9. 
The lower one contained 75 randomized digits with 
empty boxes below, which the patient was asked to 
complete with the matching symbol (32). The pa-
tients were told to complete the empty boxes from 
left to right as fast as they could, and the time to per-
form the test was measured using a chronometer. To 
avoid the learning effects, 6 parallel forms were used.
Data Analysis. MATLAB® R2008a (MA 01760-
2098, USA) software package was used for EEG data 
analysis. EEG was epoched between 500-ms pres-
timulus and 1000-ms poststimulus time window. 
Single trials with EEG or EOG amplitudes exceed-
ing ±90 µV were rejected automatically as an arti-
fact. After this procedure, EEG epochs were manu-
ally examined, and trials with other visible artifacts 
(e.g., muscle artifacts) were rejected. P3 amplitude 
was measured relatively to the mean of the 100 ms 
prestimulus baseline, and the peak latency was as-
sessed as the time from stimulus onset to maximum 
peak amplitude within the latency window of 250–
400 ms. The N1-P2 complex was identified as the 
most negative and positive points between 80 ms 
and 250 ms.
Statistical Analysis. SPSS® 16.0 package (Chi-
cago, IL 60606-6412, USA) was used for statisti-
cal analysis. First, repeated-measures ANOVA test 
with the within-subjects factors of anteroposterior 
(AP) distribution (frontal vs. central vs. parietal), 
drug condition (predrug vs. first dose vs. seventh 
day) and drug use × AP interaction were applied 
for the statistical analyses of the ERP results. The 
Greenhouse-Geisser correction was applied to the 
degrees of freedom when the repeated measure fac-
tor contained more than 2 levels, with only the cor-
rected probability values reported. 
In a second stage, P3a, P3b, and P2 amplitudes 
were reanalyzed after the data were normalized by 
vector length to assess whether the drug use × AP 
interaction was topographically robust and to evalu-
ate lateralization effects by including the left and 
right locations. For this purpose, the amplitude val-
ue of each subject was divided by the square root of 
the sum of the squared amplitudes over the 3-mid-
line electrode locations (Fz, Cz, and Pz) for each 
stimulus under each condition. ANOVA tests for 
repeated measures with the within-subjects factors 
of AP distribution (frontal vs. central vs. parietal), 
lateralization (LAT) (left vs. midline vs. right), and 
drug condition (predrug vs. first dose vs. seventh 
day) were applied to the normalized data.
To evaluate the behavioral data, again repeated 
measures ANOVA tests with the within-subjects 
factors of drug use (predrug vs. first dose vs. sev-
enth day) were applied. Each of the CPT scores (hit 
rate, omission, and commission) and DSST scores 
were evaluated individually. 
Results
There were only 5 patients who succeeded in 
quitting smoking and participated in the study un-
til the 45th day of the therapy, whereas the first 3 
recordings were available for all 10 patients. There-
fore, it was focused on the first 3 recordings, which 
were documented before the treatment, after the 
first dose, and on the seventh day.
Electrophysiological Data
Fig. 1 illustrates the grand averages ERP wave-
forms of the patients’ responses to the standard, nov-
el, and target stimuli on midline. The primary effects 
with the drug use caused an increase in the P3a and 
P3b amplitudes in responses to the novel and tar-
get stimuli, especially in the parietal region, and the 
longer P2 latency in responses to the standard stim-
uli. Tables 2, 3, and 4 display the results of statistical 
analysis applied to the electrophysiological data.
N1-P2. The analysis of the ERP data in response 
to the standard stimuli during the treatment indi-
cated that there was a significant increase in the P2 
latency after the 7-day treatment with bupropion 
SR (F2,18=4.37; P<0.05). Fig. 2 illustrates the mean 
P2 latencies from the first 3 recordings. Although 
the P2 latency in ERPs to the standard stimuli was 
slightly shorter after the first dose, it was signifi-
cantly longer after 7 days. With respect to drug use 
× AP interaction, there was an increase of border-
line significance in the P2 amplitude in response 
to the target events in the parietal area (F4,36=2.89; 
P=0.08). However, this interaction effect disap-
peared after the vector transformation. No other 
significant differences in the N1 and P2 compo-
nents were seen; the analysis of the data with respect 
to the topography showed that N1 and P2 were, as 
expected, largest in the fronto-central and parieto-
central areas, respectively.
P3a. There was a significant increase in the P3a 
amplitude in the parieto-central area on the sev-
enth day of drug administration (drug use × AP, 
F4,36=4.01; P<0.05). With respect to the AP distri-
bution, P3a showed a typical central distribution 
before the drug treatment. Displaying a central dis-
tribution after the first dose, P3a was observed to 
shift more parietal as the treatment continued. The 
vector transformation procedure increased the sig-
nificance of this drug use × AP interaction effect 
(P<0.01). The P3a latency was slightly shorter due 
to the treatment, but the difference was not statis-
tically significant. The top row in Fig. 3 presents 
the topographic distribution of P3a before the treat-
ment, after the first dose, and on the seventh day 
of treatment, which emphasizes the shift in the P3a 
topography to the parietal location on the seventh 
day. This effect is further visualized in Fig. 4 using 
the line graphs of midline amplitudes.
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Fig. 1. Grand averages ERP waveforms of the patients in responses to the standard, novel, and target stimuli on midline
Fig. 3. Topographical distributions of P3a and P3b waves
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P3b. Drug treatment did not have any signifi-
cant effect on P3b amplitudes and latencies. With 
respect to the AP distribution, P3b showed its usual 
distribution, as it was largest in the parietal area 
(F2,18=18.26; P=0.001). However, drug use  × AP 
interaction showed a change of borderline signifi-
cance in the P3b amplitude  (F4,36=2.83; P=0.076) 
(Fig. 1). Being evident at the first dose, this effect 
originated from the amplitude increase specifically 
in the parietal area. The vector transformation of 
P3b amplitude increased the significance of this 
drug use × AP interaction effect (P=0.07). The bot-
tom row in Fig. 2 presents the topographic distribu-
tion of P3b wave before the treatment, after admin-
istration of the first dose, and on the seventh day 
of treatment. It also emphasizes an increase in the 
P3b amplitude after administration of the first dose 
and on the seventh day of treatment, indicating that 
the increase of P3b amplitude after the first dose is 
localized in the parietal area. This effect is further 
visualized in Fig. 5 using the line graphs of midline 
amplitudes.
Neuropsychological Data
Table 5 presents the mean reaction time; mean 
scores of hit rate, omission, commission of the CPT; 
and the scores of the DSST before the treatment, after 
the first dose, and on the seventh day of treatment.
The analysis of the CPT data with respect to 
drug use showed an overall significant decrease in 
the reaction time (F2,18=3.87, P=0.047). There were 
no significant differences in the scores of hit rate, 
omission, and commission of the CPT. The analysis 
of the DSST scores showed a significant decrease 
on the seventh day, indicating a better performance 
(F2,18=5.73, P=0.021).
Fig. 2. P2 latency in responses to the standard events as 
a function of drug use
Predrug First Dose 7th Day
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, m
s
Factor df
P2 (Standard Events) P2 (Target Events)
Amplitude (μV) Latency (ms) Amplitude (μV) Latency (ms)
F P F P F P F P
Drug
AP
Drug × AP
2,18
2,18
4,36
1.05
14.86
2.17
NS
0.001
NS
4.37
0.14
0.94
0.032
NS
NS
0.14
6.62
2.89
NS
0.008
0.081
1.66
0.96
0.65
NS
NS
NS
NS, not significant.
Table 2. P2 Amplitude and Latency Data in Responses to Standard and Target Events
Factor df
P3a P3b
Amplitude (μV) Latency (ms) Amplitude (μV) Latency (ms)
F P F P F P F P
Drug
AP
Drug × AP
2,18
2,18
4,36
0.73
4.48
4.009
NS
0.04
0.04
0.22
4.61
1.7
NS
0.02
NS
0.82
18.26
2.83
NS
0.001
0.076
1.09
0.64
1.13
NS
NS
NS
NS, not significant.
Table 3. Data  of P3a and P3b Amplitude and Latency
Factor df
Vector Transformation
P3a Amplitude (μV) P3b Amplitude (μV)
F P F P
AP distribution
LAT                                 
Drug × AP distribution
Drug × LAT
AP distribution × LAT
Drug × AP distribution × LAT
2,18
2,18
4,36
4,36
4,36
8,72
2.38                    
8.27                 
6.20                 
0.22                    
2.33                    
2.17
NS
0.004              
0.008              
NS
NS
NS
15.79              
7.24                            
3.16                            
0.68                 
4.91               
1.02                  
0.001
0.011
0.071               
NS
0.02
NS
NS, not significant. LAT, lateralization; AP, anteroposterior.
Table 4. Data of P3a and P3b Amplitude Vector Transformation
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Discussion
The patients demonstrated a significant topo-
graphical change in the P3a amplitude (drug use 
× AP). According to the study by Friedman and 
Simpson (38), who investigated the frontal lobe 
function among young and older adults, P3 scalp 
distribution of younger adults shifted from a rela-
tively more frontal to a relatively more posterior 
focus as a function of the number of novel stimuli 
within a block, and this was not evident in the scalp 
topographies of older adults. It was suggested that 
this discrepancy was due to young people’s learn-
ing ability of categorization and identification of 
the novel stimuli as they were repeated. In other 
words, as the frontal positivity reflects the process-
ing of novel stimuli, while the novel becomes “less 
novel” and familiar, this frontal positivity shifts to 
parietal region. In line with these results, Daffner 
et al. (39) found that the N2-P3 component of 
the orienting response was larger for novel than 
repetitive background stimuli. Therefore, they 
concluded that the N2-P3 component of the ori-
enting response reflected the activity of a neural 
system involving frontal networks that dynamically 
regulated the subsequent allocation of attention 
resources to novel stimuli. Thus, a shift of the P3a 
topography to the parietal area after 7 days of bu-
propion SR treatment may reflect that the overall 
increased attention resources are relatively less al-
located for the processing of novel stimuli. From 
this point of view, a reduction in P3a in the frontal 
area suggests a decreased distractibility of the sub-
jects due to the task-irrelevant novel events, which 
may be interpreted as an augmentation of focused 
attention to the task-relevant target events. 
Additionally, an increase in P3b in the parietal 
area is in line with this hypothesis since it reflects in-
creased attention to the target events. The increased 
attention resources allocated for task-relevant target 
events indicate the augmentation of focused atten-
tion. At the same time, an increase in the P2 latency 
for standard events is thought to reflect reduced 
attention resources for the processing of standard 
events due to increased attention resources allocated 
for task-relevant target events. The delay observed 
for the P2 component, which is believed to reflect 
basic perceptual processing, was not interpreted as 
an overall difficulty for processing the stimuli since 
this delay was not observed for the later compo-
nents. The behavioral results; a decreased reaction 
time in the CPT and an improvement in the DSST 
performance due to the use of bupropion SR are 
also in line with the electrophysiological data since 
they indicate an increased focusing of attention to 
task-relevant events. 
According to the studies investigating a neuro-
chemical modulation of neural circuits, noradrener-
gic and dopaminergic agonists and antagonists have 
served as useful tools. Idazoxan, an α(2) receptor 
antagonist (increases noradrenergic activation), has 
been found to speed up the response times to tar-
gets presented at the same spatial location as the 
Fig. 4. P3a amplitude in the anteroposterior distribution Fig. 5. P3b amplitude in the anteroposterior distribution
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Variable df Predrug First Dose Seventh Day F P
Reaction time, ms
Hit rate, score
Omission, score
Commission, score
DSST, score
2,18
2,18
2,18
2,18
2,18
451.4  (63.0)
72.1  (2.0)
1.9  (0.6)
2.7  (2.6)
142.9  (42.5)
439.0  (94.6)
71.9  (2.1)
2.1  (0.7)
2.8  (3.6)
144.8  (45.6)
413.5  (72.3)
73.1  (1.6)
0.9  (0.5)
1.4  (2.1)
127.2  (40.5)
3.87
2.50
2.50
1.12
5.73
0.047
NS
NS
NS
0.021
Values are mean (standard deviation). NS, not significant.
Table 5. Results of Continuous Performance Test and Digit-Symbol Substitution Test (DSST) Before Administration of Drug, 
After the First Dose, and on the Seventh Day
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previous one, but not to those presented at a differ-
ent location (40). This was interpreted as idazoxan 
could have been attenuating the “inhibition of re-
turn effect,” which serves to maximize visual sam-
pling and search by favoring novelty. In addition to 
the body of evidence for the noradrenergic modula-
tion of attention (41), it was suggested that increas-
ing noradrenergic activation narrowed the focus of 
spatial attention and produced improvements in the 
performance of sustained attention tasks. On the 
other hand, the dopaminergic system is related to 
attention processes that require a greater degree of 
executive control such as attentional set-shifting. 
Following the administration of haloperidol, a D1/
D2 antagonist, impairments in shifting of atten-
tion were observed (42). Based on the Broadbent’s 
(43) dual process arousal mechanism, it is suggested 
that noradrenergic activation helps focus on task-
relevant behaviors by attenuating the influence of 
distracting stimuli (33). Methylphenidate, which 
increases dopaminergic activity, impaired perfor-
mance when subjects were already familiar with a 
cognitive task, but did not when they were novel 
(44). It was suggested that the novelty of the latter 
situation stimulated the Broadbent’s upper arousal 
mechanism, which in turn modulated supraoptimal 
functioning (due to methylphenidate administra-
tion) of the lower mechanism. However, in the fa-
miliar test situation, there was no stimulation of the 
compensatory “upper” mechanism, and so the drug 
effects on the lower arousal mechanism become 
evident. These effects were found to overstimulate 
the lower mechanism, leading to distractibility and 
increased responsivity, resulting in impairments in 
cognitive performance. To sum up, a tonic (lower) 
mechanism, which is mediated by dopamine and re-
lated to set-shifting/distractibility, is modulated by 
a phasic (upper) mechanism, which is mediated by 
noradrenaline and related to focused attention. 
Conclusions
Based on bupropion effects of decreased distract-
ibility and increased focused attention, bupropion 
action may be assumed to be mainly mediated by 
noradrenergic mechanisms. Additionally, regarding 
the fact that, MAO-B inhibitor selegiline, MAO-
A inhibitor moclobemide, tricyclic antidepressant 
nortriptyline, or the nicotine itself delivered by a 
patch are not individually as effective as bupropi-
on SR for the smoking cessation therapies, we can 
assume both the noradrenergic and dopaminergic 
mechanisms play a complementary role in bupro-
pion action for smoking cessation.
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